ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "remission and tocilizumab"

  • Abstract Number: 2467 • 2014 ACR/ARHP Annual Meeting

    Effectiveness and Safety of Tocilizumab in Biologics Naïve RA Patients – Interim Analysis of PMS for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-Naïve RA Patients Study

    Naoki Ishiguro1, Tatsuya Atsumi2, Masayoshi Harigai3, Tsuneyo Mimori4, Norihiro Nishimoto5, Takayuki Sumida6, Tsutomu Takeuchi7, Yoshiya Tanaka8, Nobuhiro Takagi9, Kunihiko Tanaka10 and Hisashi Yamanaka11, 1Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Medicine II School of Medicine, Hokkaido University, Sapporo, Japan, 3Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, 4Dept of Rheum & Clinical Immunology, Kyoto Univ Grad Schl of Med, Kyoto, Japan, 5Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka, Japan, 6Dept Internal Medicine, Univ of Tsukuba/Inst Clin Med, Tsukuba City, Japan, 7Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan, 8First Dept of Internal Med, U Occupa & Environ Hlth, Kitakyushu, Japan, 9Medical Science, Chugai Pharmaceutical, Tokyo, Japan, 10Pharmacovigilance, Chugai Pharmaceutical, Tokyo, Japan, 11Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose:  The all-patient PMS study of tocilizumab (TCZ) followed 7901 RA patients for 28 wks. That study (hereafter, PMS7901) showed patients with a high probability…
  • Abstract Number: 275 • 2013 ACR/ARHP Annual Meeting

    Changes In Serum IL-18 Level In Systemic Juvenile Idiopathic Arthritis Patients Who Attained Drug-Free Remission By Tocilizumab

    Tomohiro Kubota1, Syuji Takei2, Yuichi Yamasaki1, Junko Yasumura3, Naomi Kuwada4, Yukiko Nonaka5, Tomoko Takezaki5, Tsuyoshi Yamatou5, Tomokazu Nagakura6, Yasuhito Nerome5, Hiroyuki Imanaka5 and Harumi Akaike5, 1Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, 2School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, 3Dept of Pediatrics, Graduate School of Biomedical Sciences, Faculty of Medicine, Hiroshima University, Hiroshima City, Japan, 4Dept of Pediatrics, Faculuty of Medicine, Kumamoto University, Kumamoto City, Japan, 5Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, 6Department of Pediatrics, House of Meguminoseibo, Usuki, Japan

    Background/Purpose: Tocilizumab (TCZ), anti-human interleukin-6 receptor monoclonal antibody, was the first biologic agent used in the treatment of systemic juvenile idiopathic arthritis (sJIA) in Japan.…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology